<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196830</url>
  </required_header>
  <id_info>
    <org_study_id>SZ5601</org_study_id>
    <nct_id>NCT03196830</nct_id>
  </id_info>
  <brief_title>CAR-T for R/R B-NHL</brief_title>
  <official_title>Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single arm study to investigate the efficacy and safety of CAR-T targeted&#xD;
      CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients&#xD;
      will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for&#xD;
      at least 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>One months after CAR-T cells were infused</time_frame>
    <description>Rate of complete remission and patial remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse toxicity</measure>
    <time_frame>Day 0, day 4, week 1, week 3, week 4, month 2, month 24 after CAR-T cells were infused</time_frame>
    <description>Accordingto CTCAE 4.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T cell survival</measure>
    <time_frame>every week in first 4 weeks after CAR-T cells infusion, then every 3 months for 2 years, then every 6 months for next 2 years</time_frame>
    <description>the survival of CAR-T cells detected in patients' peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <condition>CAR - T CD19/CD20/CD22/CD30</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group of patients who received CAR-T treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T</intervention_name>
    <description>For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological detection confirmed CD19/CD20/CD22/CD30 postive non-Hodgkin lymphoma&#xD;
&#xD;
          -  Recieved more than 2 lines of chemotherapy&#xD;
&#xD;
          -  With contraindications of hematopoietic stem cell transplantation or relapse after&#xD;
             hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Expected survival more than 3 months&#xD;
&#xD;
          -  Karmofsky performance score ≤ 60, and ECOG ≥ 2.&#xD;
&#xD;
          -  Enough organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper&#xD;
             limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT &lt; 2 × upper limitation of normal;&#xD;
             SpO2 &gt; 92%&#xD;
&#xD;
          -  CBC results: Hb ≥ 80g/L, ANC &gt; 1 × 10E9/L, Plt ≥ 50 × 10E9/L&#xD;
&#xD;
          -  Results of pregnant test should be negative, and agree to conception control during&#xD;
             treatment and 1 year after CAR-T infusion&#xD;
&#xD;
          -  With measurable disease&#xD;
&#xD;
          -  Written informed consent could be acquired&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received immunol suppression treatment or steroids in recent 1 week before recruitment&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  HIV positive patients&#xD;
&#xD;
          -  Active HBV or HCV infection&#xD;
&#xD;
          -  Women in pregnancy and lactation&#xD;
&#xD;
          -  Refuse to conception control during treatment and 1 year after CAR-T infusion&#xD;
&#xD;
          -  Uncured malignancies other than non-Hodgkin lymphoma&#xD;
&#xD;
          -  Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma&#xD;
&#xD;
          -  Inheritated immune deficiancy&#xD;
&#xD;
          -  Severe heart disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cai-Xia Li</last_name>
    <phone>86 512 67781856</phone>
    <email>licaixia@suda.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Chen, M.D.</last_name>
      <phone>+86 512 67781856</phone>
      <email>chenjiasuzhou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapse/refractory non-Hodgkin lymphoma</keyword>
  <keyword>CAR - T CD19/CD20/CD22/CD30</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

